August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with
Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS),
Louisville, KY, June 29, 2017 – Apellis Pharmaceuticals, Inc. today provided an update on clinical outcomes in its two ongoing Phase 1b clinical trials with
Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only
Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer IgE antibodies shown to offer greater efficacy than
Dr Moore was Founder Chairman of Mission Therapeutics and PsiOxus Therapeutics with each of which he continues to serve as a non-executive director. He also
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of
Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election
Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel